Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSCW) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to -$1.9 million.

  • Ensysce Biosciences' Cash from Operations fell 8290.21% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.0 million, marking a year-over-year increase of 1751.58%. This contributed to the annual value of -$7.5 million for FY2024, which is 3040.16% up from last year.
  • Per Ensysce Biosciences' latest filing, its Cash from Operations stood at -$1.9 million for Q3 2025, which was down 8290.21% from -$2.7 million recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Cash from Operations ranged from a high of -$132312.0 in Q2 2021 and a low of -$6.7 million during Q3 2022
  • In the last 5 years, Ensysce Biosciences' Cash from Operations had a median value of -$2.7 million in 2025 and averaged -$2.7 million.
  • As far as peak fluctuations go, Ensysce Biosciences' Cash from Operations tumbled by 325607.81% in 2022, and later skyrocketed by 6630.11% in 2023.
  • Ensysce Biosciences' Cash from Operations (Quarter) stood at -$3.8 million in 2021, then increased by 12.53% to -$3.3 million in 2022, then soared by 45.33% to -$1.8 million in 2023, then skyrocketed by 57.59% to -$764090.0 in 2024, then plummeted by 144.24% to -$1.9 million in 2025.
  • Its last three reported values are -$1.9 million in Q3 2025, -$2.7 million for Q2 2025, and -$1.7 million during Q1 2025.